Chlordecone (CD; Kepone™) is a carcinogenic organochlorine insecticide with neurological, reproductive, and developmental toxicity that was widely used in the French West Indies (FWI) from 1973 to 1993 to fight banana weevils.
Capturing Interpatient Variability with SimPops
SimPops provide significant value for drug development. "The SimPops are the Crown Jewel".
Financial Conflict of Interest Policy
Policy on Disclosure and Management of Financial Conflicts of Interest related to Public Health Service Research
Synthesis and Characterization of Novel 2-Pyridine Mono(thio)carbohydrazones as Promising Antioxidant and Antimicrobial Agents. Experimental and Theoretical Approach
Four new derivatives of 2-pyridine mono(thio)carbohydrazones were synthesized by condensation of carbaldehydes with carbohydrazide and thiocarbohydrazide following a known procedure.
Applications of PBPK/PBBM modeling in generic product development: An industry perspective
Physiologically based pharmacokinetic (PBPK) modeling and physiologically based biopharmaceutics modeling (PBBM) are invaluable tools with wide applications during drug discovery and development stages.
Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review
There are a multitude of different modelling techniques that have been used for inhaled drugs.
Alternative experimental approaches to reduce animal use in biomedical studies
We review experimental approaches that can be used instead of in vivo studies involving vertebrate animal models and human clinical trials.
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
Small molecule developability challenges have been well documented over the last two decades.
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
Collaborative research effort will further enhance the ACAT model to aid scientists in the detailed understanding of local drug disposition in the gastrointestinal tract
Predictive Performance of Next Generation Human Physiologically Based Kinetic (PBK) Models Based on In Vitro and In Silico Input Data
The goal of the present study was to assess the predictive performance of a generic human physiologically based kinetic (PBK) model based on in vitro and in silico input data and the effect of using different input approaches for chemical parameterization on those predictions.
January 2022 GastroPlus Newsletter
Amazingly we now find ourselves at the beginning of a new and exciting year for modeling and simulation!
Simulations Plus Enters New Collaboration with Leading Animal Health Company
Partnership will expand virtual animal models to support veterinary medicine and next-generation alternatives to animal testing
In silico predictions of absorption of MDI substances after dermal or inhalation exposures to support a category based read-across assessment
Methylenediphenyl diisocyanate (MDI) substances used polyurethane production can range from their simplest monomeric forms (e.g., 4,4′-MDI) to mixtures of the monomers with various homologues, homopolymer, and prepolymer derivatives.
Preferential solvation study of (Z)-N-benzyl-2-{5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)acetamide (3) in {NMP (1) + Water (2)} co-solvent mixture and GastroPlus software based in vitro simulation
(Z)-N-benzyl-2-{5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)acetamide (3) (SE11) is a newly synthesized benzylidine thiazolidinedione to inhibit aldose reductase (AR) to control Diabetes Mellitus (DM) and related complications.
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
Total revenue growth of 16%; Software revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 25%
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close... January 6, 2022.